Also trades as: 2186.HK (HKSE) · $vol 10M
LYPHF OTC
Luye Pharma Group Ltd.
1W: +0.0%
1M: +0.0%
3M: +32.3%
YTD: -27.9%
1Y: +0.8%
3Y: -64.0%
$0.27
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$168M
-89.5% ▼
5Y CAGR: -37.4%
Capital Expenditures
$1.7B
-46.6% ▼
5Y CAGR: -11.9%
Free Cash Flow
-$1.5B
-458.1% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$1.7B
+85.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $942M | -$75M | $670M | $700M | $839M |
| Depreciation & Amort. | $511M | $582M | $671M | $702M | $791M |
| Stock-Based Comp. | $51M | $50M | $25M | $21M | $21M |
| Change in Working Capital | -$300M | -$418M | $320M | $398M | -$1.2B |
| Other Non-Cash Items | $336M | $355M | -$33M | -$225M | -$250M |
| Operating Cash Flow | $1.0B | $182M | $1.7B | $1.6B | $168M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.5B | -$1.5B | -$1.2B | -$633M | -$596M |
| Acquisitions (Net) | -$451M | -$809M | $0 | -$1.4B | -$634M |
| Investment Purchases | -$2.9B | -$4.0B | -$3.5B | -$1.6B | -$2.4B |
| Investment Sales | $4.2B | $1.9B | $2.9B | $2.6B | $3.6B |
| Other Investing | $814M | $971M | $92M | -$371M | -$1.4B |
| Investing Cash Flow | $138M | -$3.4B | -$1.7B | -$1.4B | -$1.5B |
| — Financing Activities — | |||||
| Net Debt Issuance | $1.4B | -$406M | -$666M | -$478M | $1.9B |
| Stock Repurchased | -$78M | $0 | $0 | $0 | $0 |
| Dividends Paid | -$175M | $0 | $0 | $0 | $0 |
| Other Financing | -$933M | $1.2B | $531M | $397M | $1.1B |
| Financing Cash Flow | $254M | $1.9B | $54M | $842M | $3.0B |
| Net Change in Cash | $1.5B | -$1.4B | -$115M | $915M | $1.7B |
| Cash End of Period | $3.9B | $2.4B | $2.3B | $3.2B | $4.9B |
| Free Cash Flow | -$486M | -$1.4B | $490M | $430M | -$1.5B |